ANGLE plc (AGL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ANGLE plc (AGL) has a cash flow conversion efficiency ratio of -0.385x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-4.50 Million ≈ $-547.76 USD) by net assets (GBX11.69 Million ≈ $1.42K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ANGLE plc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how ANGLE plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of ANGLE plc for a breakdown of total debt and financial obligations.
ANGLE plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ANGLE plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
G2Power Co. Ltd.
KQ:388050
|
-0.043x |
|
Green Leaf Innovations Inc.
NASDAQ:GRLFD
|
N/A |
|
DOLPHIN DRILL. A.S. NK 10
F:L33
|
N/A |
|
Renalytix AI plc
LSE:RENX
|
4.746x |
|
Fiske PLC
LSE:FKE
|
0.090x |
|
QVC Group Inc.
NASDAQ:QVCGB
|
-0.001x |
|
Kendrick Resources PLC
LSE:KEN
|
-0.071x |
|
Montage Gold Corp.
TO:MAU
|
-0.033x |
Annual Cash Flow Conversion Efficiency for ANGLE plc (2001–2024)
The table below shows the annual cash flow conversion efficiency of ANGLE plc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see AGL stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX18.44 Million ≈ $2.24K |
GBX-13.45 Million ≈ $-1.64K |
-0.729x | -15.70% |
| 2023-12-31 | GBX22.94 Million ≈ $2.79K |
GBX-14.46 Million ≈ $-1.76K |
-0.630x | -57.33% |
| 2022-12-31 | GBX40.06 Million ≈ $4.87K |
GBX-16.05 Million ≈ $-1.95K |
-0.401x | -15.32% |
| 2021-12-31 | GBX40.33 Million ≈ $4.91K |
GBX-14.01 Million ≈ $-1.70K |
-0.347x | -52.02% |
| 2020-12-31 | GBX34.34 Million ≈ $4.18K |
GBX-7.85 Million ≈ $-954.87 |
-0.229x | +27.02% |
| 2019-12-31 | GBX26.60 Million ≈ $3.24K |
GBX-8.33 Million ≈ $-1.01K |
-0.313x | +17.22% |
| 2019-04-30 | GBX19.34 Million ≈ $2.35K |
GBX-7.31 Million ≈ $-889.90 |
-0.378x | +11.80% |
| 2018-04-30 | GBX15.88 Million ≈ $1.93K |
GBX-6.81 Million ≈ $-828.82 |
-0.429x | +48.85% |
| 2017-04-30 | GBX8.81 Million ≈ $1.07K |
GBX-7.38 Million ≈ $-898.30 |
-0.838x | +7.83% |
| 2016-04-30 | GBX5.24 Million ≈ $636.95 |
GBX-4.76 Million ≈ $-579.40 |
-0.910x | -168.19% |
| 2015-04-30 | GBX10.09 Million ≈ $1.23K |
GBX-3.42 Million ≈ $-416.36 |
-0.339x | +16.30% |
| 2014-04-30 | GBX5.51 Million ≈ $671.02 |
GBX-2.23 Million ≈ $-271.93 |
-0.405x | -97.56% |
| 2013-04-30 | GBX6.79 Million ≈ $825.71 |
GBX-1.39 Million ≈ $-169.38 |
-0.205x | +16.39% |
| 2012-04-30 | GBX4.41 Million ≈ $536.08 |
GBX-1.08 Million ≈ $-131.53 |
-0.245x | -37.30% |
| 2011-04-30 | GBX4.53 Million ≈ $551.54 |
GBX-810.00K ≈ $-98.55 |
-0.179x | -61.09% |
| 2010-04-30 | GBX4.16 Million ≈ $505.67 |
GBX-461.00K ≈ $-56.09 |
-0.111x | +46.35% |
| 2009-04-30 | GBX3.82 Million ≈ $464.91 |
GBX-790.00K ≈ $-96.12 |
-0.207x | +34.06% |
| 2008-04-30 | GBX7.22 Million ≈ $878.59 |
GBX-2.26 Million ≈ $-275.46 |
-0.314x | +71.32% |
| 2007-04-30 | GBX5.70 Million ≈ $693.16 |
GBX-6.23 Million ≈ $-757.65 |
-1.093x | -303.88% |
| 2006-04-30 | GBX14.48 Million ≈ $1.76K |
GBX-3.92 Million ≈ $-476.83 |
-0.271x | 0.00% |
| 2005-04-30 | GBX14.48 Million ≈ $1.76K |
GBX-3.92 Million ≈ $-476.83 |
-0.271x | -5819.15% |
| 2004-04-30 | GBX10.99 Million ≈ $1.34K |
GBX52.00K ≈ $6.33 |
0.005x | +100.44% |
| 2003-04-30 | GBX546.00K ≈ $66.43 |
GBX-592.00K ≈ $-72.03 |
-1.084x | +4.59% |
| 2002-04-30 | GBX909.00K ≈ $110.60 |
GBX-1.03 Million ≈ $-125.69 |
-1.136x | -23.10% |
| 2001-04-30 | GBX1.30 Million ≈ $158.29 |
GBX-1.20 Million ≈ $-146.13 |
-0.923x | -- |
About ANGLE plc
ANGLE plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ C… Read more